DBV Technologies reported a net loss of $98.0 million for the six months ended June 30, 2026, including a $50.4 million loss in Q2. The company disclosed cash and cash equivalents of $174.9 million as of June 30, 2026, which management says funds operations into Q3 2027. DBV continues regulatory engagement with the FDA and anticipates submitting the BLA for the VIASKIN Peanut Patch for children 4–7 in Q3 2026.

Financial Highlights

  • Net loss: $98.0 million for the six months ended June 30, 2026; $50.4 million for the three months ended June 30, 2026.
  • Operating income: $1.6 million for the six months ended June 30, 2026 (including $0.7 million in Q2 2026).
  • Research & Development expenses: $64.6 million for the six months ended June 30, 2026 (including $31.2 million in Q2 2026).
  • Selling, General & Administrative expenses: increased vs. prior year (noted increases of $20.7 million for six months and $11.2 million for three months versus 2025).
  • Cash and cash equivalents: $174.9 million as of June 30, 2026; management estimates funding into third quarter of 2027.

Business Highlights

  • Regulatory progress: Continued productive, iterative engagement with the FDA; no additional data requested and BLA submission for VIASKIN Peanut Patch (children 4–7) anticipated in Q3 2026.
  • Clinical programs: Closed recruitment for the COMFORT Toddlers supplemental safety study (toddlers 1–3 years) and initiated the THRIVE study in infants aged 6–12 months to evaluate long-term treatment outcomes.
  • Commercial preparedness: Investments in U.S. launch readiness across Medical Affairs, Sales, Market Access, Marketing, Account Management, Quality, and Pharmacovigilance; pre‑commercial inventory being built.
  • Corporate visibility and engagement: Presented subgroup analyses from phase 3 VITESSE at major allergy congresses (AAAAI, EAACI) and gained inclusion in several European indices (CAC Mid 60, SBF 120, Euronext Tech Leaders, MSCI EMEA Small Cap).

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.